Fibrogenic reactions in lung disease

Annual Review of Pathology: Mechanisms of Disease

Volumn 5, Issue , 2010, Pages 77-98

  Araya, Jun ^a   Nishimura, Stephen L ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Airway; Asthma; Emphysema; Interstitial fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CIGARETTE SMOKE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ET 1 PROTEIN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 4; LATENCY ASSOCIATED PEPTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

AIRWAY; ASTHMA; B LYMPHOCYTE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL TRANSDIFFERENTIATION; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; EMPHYSEMA; ENVIRONMENT; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; FIBROSING ALVEOLITIS; GENE ACTIVATION; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNOPHENOTYPING; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG EDEMA; LUNG FIBROBLAST; LUNG FIBROSIS; MACROPHAGE; MEMBRANE PERMEABILITY; MESENCHYMAL STEM CELL; MYOFIBROBLAST; NEUTROPHIL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; FIBROBLAST; LUNG DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASTHMA; EMPHYSEMA; FIBROBLASTS; HUMANS; LUNG DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77949887505     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.4.110807.092217     Document Type: Review

References (135)

1. Walker R, Parsche F, Bierbrier M, McKerrow JH. 1987. Tissue identification and histologic study of six lung specimens from Egyptian mummies. Am. J. Phys. Anthropol. 72:43-48
2. Katzenstein AL, Mukhopadhyay S, Myers JL. 2008. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum. Pathol. 39:1275-1294
3. Thannickal VJ. 2006. Idiopathic interstitial pneumonia: a clinicopathological perspective. Semin. Respir. Crit. Care Med. 27:569-573
4. Hogg JC, Macklem PT, Thurlbeck WM. 1968. Site and nature of airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. 278:1355-1360
5. Hogg JC. 2008. Lung structure and function in COPD. Int. J. Tuberc. Lung Dis. 12:467-479
6. Broide DH. 2008. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J. Allergy Clin. Immunol. 121:560-572
7. Halpin DM, Miravitlles M. 2006. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc. Am. Thorac. Soc. 3:619-623 (Pubitemid 44411630)
8. Akinbami L. 2006. Asthma prevalence, health care use and mortality: United States, 2003-05. Hyattsville, MD: Cent. Dis. Control Prev., Natl. Cent. Health Stat. http://www.cdc.gov/nchs/products/pubs/ pubd/hestats/ashtma03-05/ asthma03-05.htm. Accessed May 5, 2009
9. Raghu G,Weycker D, Edelsberg J, Bradford WZ, Oster G. 2006. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174:810-816
10. O'Donnell RA, Davies DE, Holgate ST. 2002. Airway remodeling. In Asthma and COPD, ed. PJ Barnes, JM Drazen, S Rennard, NC Thomson, pp. 67-78. New York: Academic
11. James AL, Wenzel S. 2007. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 30:134-155
12. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, et al. 2006. Epithelial damage and angiogenesis in the airways of children with asthma. Am. J. Respir. Crit. Care Med. 174:975-981
13. Dunnill MS,Massarella GR, Anderson JA. 1969.Acomparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 24:176-179
14. Pare PD, Bai TR, Roberts CR. 1997. The structural and functional consequences of chronic allergic inflammation of the airways. Ciba. Found. Symp. 206:71-86, 89, 106-110
15. Ward C, Johns DP, Bish R, Pais M, Reid DW, et al. 2001. Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma. Am. J. Respir. Crit. Care Med. 164:1718-1721
16. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. 1989. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev. Respir. Dis. 140:1745-1753
17. Gingter C, Wilm S, Abholz HH. 2008. Is COPD a rare disease? Prevalence and identification rates in smokers aged 40 years and over within general practice in Germany. Fam. Pract. 26:3-9
18. Vandevoorde J,Verbanck S, Gijssels L, Schuermans D, Devroey D, et al. 2007. Early detection of COPD: a case finding study in general practice. Respir. Med. 101:525-530
19. Hogg JC, Chu F, Utokaparch S,Woods R, Elliott WM, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350:2645-2653
20. Niewoehner DE, Kleinerman J, Rice DB. 1974. Pathologic changes in the peripheral airways of young cigarette smokers. N. Engl. J. Med. 291:755-758
21. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, et al. 1978. The relations between structural changes in small airways and pulmonary-function tests. N. Engl. J. Med. 298:1277-1281
22. Berend N, Thurlbeck WM. 1982. Correlations of maximum expiratory flow with small airway dimensions and pathology. J. Appl. Physiol. 52:346-351
23. Matsuba K, Shirakusa T, Kuwano K, Hayashi S, Shigematsu N. 1987. Small airways disease in patients without chronic air-flow limitation. Am. Rev. Respir. Dis. 136:1106-1111
24. Bosken CH,Wiggs BR, Pare PD, Hogg JC. 1990. Small airway dimensions in smokers with obstruction to airflow. Am. Rev. Respir. Dis. 142:563-570
25. Hogg JC, Timens W. 2008. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. Mech. Dis. 4:435-459
26. Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D. 2000. Telomerase in alveolar epithelial development and repair. Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1191-98
27. Strieter RM. 2005. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 128:526S-32S
28. Visscher DW, Myers JL. 2006. Histologic spectrum of idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 3:322-329
29. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. 2003. Airway structural alterations selectively associated with severe asthma. Am. J. Respir. Crit. Care Med. 167:1360-1368
30. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. 1989. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev. Respir. Dis. 140:1745-1753
31. RocheWR,Beasley R,Williams JH, Holgate ST. 1989. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1:520-524
32. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, et al. 2001. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am. J. Physiol. Lung Cell Mol. Physiol. 280:L165-72
33. Luppi F, Aarbiou J, van Wetering S, Rahman I, de Boer WI, et al. 2005. Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. Respir. Res. 6:140
34. Barnes PJ. 2006. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 148:245-254
35. Prescott E, Lange P,Vestbo J. 1995. Chronic mucus hypersecretion inCOPDand death from pulmonary infection. Eur. Respir. J. 8:1333-1338
36. Weibel ER. 1984. The Pathway for Oxygen. Cambridge, MA: Harvard Univ. Press. 448 pp.
37. Nishimura SL, Finkbeiner W. 2005. General features of respiratory pathology. In Murray and Nadel's Textbook of RespiratoryMedicine, ed. RJ Mason, JF Murray, VC Broaddus, JA Nadel, pp. 407-448 Philadelphia: Elsevier Saunders. 4th ed.
38. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. 2001. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 344:573-579
39. Wei ML. 2006. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res. 19:19-42
40. Young LR, Pasula R, Gulleman PM, Deutsch GH,McCormack FX. 2007. Susceptibility of Hermansky- Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am. J. Respir. Cell Mol. Biol. 37:67-74
41. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. 2006. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am. J. Respir. Crit. Care Med. 174:654-658
42. Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, et al. 2003. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am. J. Respir. Crit. CareMed. 167:1410-1415
43. Desmouliere A, Redard M, Darby I, Gabbiani G. 1995. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146:56-66
44. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. 2007. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170:1807-1816
45. Sugiura H, Liu X, Duan F, Kawasaki S, Togo S, et al. 2007. Cultured lung fibroblasts from ovalbuminchallenged "asthmatic" mice differ functionally from normal. Am. J. Respir. Cell Mol. Biol. 37:424-430
46. Araya J, Cambier S, Markovics JA, Wolters P, Jablons D, et al. 2007. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J. Clin. Investig. 117:3551-3562
47. Ramos C, Montano M, García-Alvarez J, Ruiz V, Uhal BD, et al. 2001. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol. 24:591-598
48. Torry DJ, Richards CD, Podor TJ, Gauldie J. 1994. Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue. J. Clin. Investig. 93:1525-1532
49. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, et al. 2002. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. USA 99:12877-12882
50. Eyden B. 2008. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J. Cell Mol. Med. 12:22-37
51. Ross R, Everett NB, Tyler R. 1970.Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J. Cell Biol. 44:645-654
52. Desmouliere A,Geinoz A,Gabbiani F,Gabbiani G,(1993)Transforming growth factor-β 1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122:103-111.
53. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, et al. 2003. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278:12384-12389
54. Singh SR, Hall IP. 2008. Airway myofibroblasts and their relationship with airway myocytes and fibroblasts. Proc. Am. Thorac. Soc. 5:127-132
55. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. 1995. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Investig. 95:859-873
56. Zhang K, Rekhter MD, Gordon D, Phan SH. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. Pathol. 145:114-125 (Pubitemid 24217490)
57. Lama VN,Smith L,Badri L,Flint A,Andrei AC,et al. 2007. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J. Clin. Investig. 117:989-996.
58. Lama VN, Smith L, Badri L, Flint A, Andrei AC, et al. 2007. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J. Clin. Investig. 117:989-996
59. Ross R, Everett NB, Tyler R. 1970.Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J. Cell Biol. 44:645-654
60. Bucala R, Spiegel LA, Chesney J, HoganM,Cerami A. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1:71-81
61. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, et al. 2007. Interleukin-1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA 104:11002-11007
62. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. 2004. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Investig. 113:243-252
63. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, et al. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Investig. 114:438-446
64. Yokota T, Kawakami Y, Nagai Y, Ma JX, Tsai JY, et al. 2006. Bone marrow lacks a transplantable progenitor for smooth muscle type α-actin- expressing cells. Stem Cells 24:13-22
65. Hay ED. 1995. An overview of epithelio-mesenchymal transformation. Acta Anat. (Basel) 154:8-20
66. Tarin D, Thompson EW, Newgreen DF. 2005. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65:5996-6001
67. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715
68. Zavadil J, Bottinger EP. 2005. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24:5764-5774
69. Herzlinger D. 2002. Renal interstitial fibrosis: remembrance of things past? J. Clin. Investig. 110:305-306
70. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Investig. 110:341-350
71. Ekblom P. 1989. Developmentally regulated conversion of mesenchyme to epithelium. FASEB J. 3:2141-2150
72. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, et al. 2006. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 103:13180-13185
73. Larsson O, Diebold D, Fan D, Peterson M, Nho RS, et al. 2008. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS ONE 3:e3220
74. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. 2007. TGF-β, Smad3 and the process of progressive fibrosis. Biochem. Soc. Trans. 35:661-664
75. Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214:199-210
76. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851
77. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, et al. 1998. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93:1159-1170
78. Morris DG, Huang X, Kaminski N,Wang Y, Shapiro SD, et al. 2003. Loss of integrin α(v)β6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 422:169-173
79. Sheppard D. 2006. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 3:413-417
80. Kenyon NJ,WardRW,McGrew G, Last JA. 2003. TGF-β1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 58:772-777
81. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. 1997. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Investig. 100:768-776
82. Giri SN, Hyde DM, Hollinger MA. 1993. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax 48:959-966
83. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, et al. 2008. Inhibition of integrin α(v)β6, an activator of latent transforming growth factor-β, prevents radiation-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 177:82-90
84. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGF-β activation. J. Cell Sci. 116:217-224
85. Massague J, Gomis RR. 2006. The logic of TGFβ signaling. FEBS Lett. 580:2811-2820
86. Barcellos-Hoff MH, Dix TA. 1996. Redox-mediated activation of latent transforming growth factor-β1. Mol. Endocrinol. 10:1077-1083
87. Jullien P, Berg TM, Lawrence DA. 1989. Acidic cellular environments: activation of latent TGF-β and sensitization of cellular responses to TGF-β and EGF. Int. J. Cancer 43:886-891
88. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, et al. 1999. The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328
89. Nunes I, Shapiro RL, Rifkin DB. 1995. Characterization of latentTGF-βactivation by murine peritoneal macrophages. J. Immunol. 155:1450-1459
90. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. 2005. Increased expression of integrin α(v)β3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J. Immunol. 175:7708-7718
91. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. 2007. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J. Cell Biol. 179:1311-1323
92. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, et al. 2002. The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J. Cell Biol. 157:493-507
93. Yu Q, Stamenkovic I. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14:163-176
94. Aluwihare P, Mu Z, Zhao Z, Yu D, Weinreb PH, et al. 2009. Mice that lack activity of α(v)β6- and α(v)β8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 122:227-232
95. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, et al. 2007. Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice. J. Cell Biol. 176:787-793
96. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF. 2002. β8 integrins are required for vascular morphogenesis in mouse embryos. Development 129:2891-2903
97. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, et al. 1993. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770-774
98. Proctor JM, Zang K,Wang D,Wang R, Reichardt LF. 2005. Vascular development of the brain requires β8 integrin expression in the neuroepithelium. J. Neurosci. 25:9940-9948
99. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, et al. 1997. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. CareMed. 156:591-599
100. Ueda T, Niimi A, Matsumoto H, Takemura M, Yamaguchi M, et al. 2008. TGFB1 promoter polymorphism C-509T and pathophysiology of asthma. J. Allergy Clin. Immunol. 121:659-664
101. Oukka M. 2007. Interplay between pathogenic Th17 and regulatory T cells. Ann. Rheum. Dis. 66(Suppl. 3):87-90
102. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, et al. 1998. Transforming growth factor-β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158:1951-1957
103. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, et al. 2001. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 163:1476-1483
104. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, et al. 2004. The transforming growth factor- β1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum. Mol. Genet. 13:1649-1656
105. Wang RD, Wright JL, Churg A. 2005. Transforming growth factor-β1 drives airway remodeling in cigarette smoke-exposed tracheal explants. Am. J. Respir. Cell Mol. Biol. 33:387-393
106. Pociask DA, Sime PJ, Brody AR. 2004. Asbestos-derived reactive oxygen species activate TGF-β1. Lab Investig. 84:1013-1023
107. Chua F, Laurent GJ. 2006. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac. Soc. 3:424-427
108. Khalil N, O'Connor RN, Unruh HW,Warren PW, Flanders KC, et al. 1991. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 5:155-162
109. Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, et al. 2003. Transforming growth factor- β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168:431-435
110. Roy SG, Nozaki Y, Phan SH. 2001. Regulation of α-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int. J. Biochem. Cell Biol. 33:723-734
111. Cutroneo KR. 2007. TGF-β-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 15(Suppl. 1):S54-60
112. HuB,Wu Z, Liu T, UllenbruchMR,Jin H, Phan SH. 2007. Gut-enriched Kruppel-like factor interaction with Smad3 inhibits myofibroblast differentiation. Am. J. Respir. Cell Mol. Biol. 36:78-84
113. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β(1). J. Exp. Med. 194:809-821
114. Chen Q, Rabach L, Noble P, Zheng T, Lee CG, et al. 2005. IL-11 receptor α in the pathogenesis of IL-13-induced inflammation and remodeling. J. Immunol. 174:2305-2313
115. Leask A, Abraham DJ. 2003. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol. 81:355-363
116. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, et al. 2007. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor α in human lung fibroblasts. Arthritis Rheum. 56:4189-4194
117. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, et al. 2008. BUILD-1: a randomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177:75-81
118. Gharaee-Kermani M, Denholm EM, Phan SH. 1996. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 271:17779-17784
119. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, et al. 2006. Ligation of protease-activated receptor 1 enhances α(v)β6 integrin-dependent TGF-β activation and promotes acute lung injury. J. Clin. Investig. 116:1606-1614
120. Howell DC, Goldsack NR,Marshall RP, McAnulty RJ, Starke R, et al. 2001. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycininduced pulmonary fibrosis. Am. J. Pathol. 159:1383-1395
121. Doz E, Noulin N, Boichot E, Guenon I, Fick L, et al. 2008. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J. Immunol. 180:1169-1178
122. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. 2005. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J. Immunol. 175:5390-5395
123. Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. 1990. Interferon-β reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-β in normal human fibroblasts. Eur. J. Clin. Investig. 20:487-493
124. Prior C, Haslam PL. 1992. In vivo levels and in vitro production of interferon-β in fibrosing interstitial lung diseases. Clin. Exp. Immunol. 88:280-287
125. Kim JH, Kim HY, Kim S, Chung JH, Park WS, Chung DH. 2005. Natural killerT(NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-β. Am. J. Pathol. 167:1231-1241
126. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. 1999. A preliminary study of long-term treatment with interferon-β-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341:1264-1269
127. Scotton CJ, Chambers RC. 2007. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132:1311-1321
128. Springer J, Scholz FR, Peiser C, Groneberg DA, Fischer A. 2004. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitorySMAD6 and 7 by cigarette smoke. Biol. Chem. 385:649-653
129. Nakao A, Sagara H, Setoguchi Y, Okada T, Okumura K, et al. 2002. Expression of Smad7 in bronchial epithelial cells is inversely correlated to basement membrane thickness and airway hyperresponsiveness in patients with asthma. J. Allergy Clin. Immunol. 110:873-878
130. Hershenson MB, Brown M, Camoretti-Mercado B, Solway J. 2008. Airway smooth muscle in asthma. Annu. Rev. Pathol. Mech. Dis. 3:523-555
131. Jeffery PK. 2000. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 117:251-60S
132. Lynch DA, Travis WD,Muller NL, Galvin JR, Hansell DM, et al. 2005. Idiopathic interstitial pneumonias: CT features. Radiology 236:10-21
133. Barnes PJ. 2008. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Investig. 118:3546-3556
134. Barnes PJ. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8:183-192
135. Aluwihare P, Munger JS. 2008. What the lung has taught us about latent TGF-β activation. Am. J. Respir. Cell Mol. Biol. 39:499-502